Tango Therapeutics doses first patient in cancer drug combo trial

BOSTON - Tango Therapeutics (NASDAQ:TNGX), whose stock has surged nearly 58% over the past six months according to InvestingPro data, has dosed the first patient in a Phase 1/2 trial testing its TNG462 drug in combination with Revolution Medicines’ RAS inhibitors for patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer, the company announced Friday.

The trial (NCT06922591) is evaluating TNG462 in combination with either daraxonrasib or zoldonrasib in patients whose cancers have both an MTAP deletion and a RAS mutation. According to the company, which maintains a strong liquidity position with a current ratio of 6.26 and more cash than debt on its balance sheet, almost all MTAP-deleted pancreatic cancers and approximately 30% of lung cancers have a co-occurring RAS mutation.

The study will assess safety, pharmacokinetics, pharmacodynamics and antitumor activity of the combinations. Preclinical data has shown strong combination activity between TNG462 and either of the Revolution Medicines compounds.

TNG462, described as an MTA-cooperative PRMT5 inhibitor, is also being evaluated as a monotherapy in a separate Phase 1/2 trial, with data expected in the second half of 2025. The company stated that this upcoming data could inform a registrational trial in pancreatic cancer next year and advance development plans for lung cancer.

Adam Crystal, President of Research and Development at Tango Therapeutics, said the combinations could potentially become "transformative therapies" based on single-agent clinical data to date showing the molecules are well-tolerated and active in pancreatic and lung cancers.

Tango Therapeutics is a clinical-stage biotechnology company focused on discovering precision cancer medicines using the genetic principle of synthetic lethality.

This article is based on a press release statement from Tango Therapeutics.

In other recent news, Tango Therapeutics has initiated a Phase 1/2 clinical trial for its drug candidate TNG456, aimed at treating MTAP-deleted solid tumors, particularly glioblastoma (GBM). This trial will evaluate the safety and efficacy of TNG456 both as a standalone treatment and in combination with another drug, abemaciclib. Tango’s President of Research and Development, Adam Crystal, emphasized the potential impact of TNG456, noting that a significant portion of GBM patients could benefit from this treatment. Meanwhile, H.C. Wainwright has maintained a Buy rating for Tango Therapeutics, with a $13 price target, following the company’s recent financial disclosures. Tango reported a net loss of $0.35 per share for the fourth quarter of 2024, aligning closely with the analyst’s expectations. The company’s R&D and SG&A expenses were slightly below estimates, and Tango ended the year with a strong cash position of $257.9 million. H.C. Wainwright projects that this financial reserve will sustain Tango’s operations into the third quarter of 2026. The analyst firm has also adjusted its projection for Tango’s full-year 2025 net loss to $1.52 per share.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.